CN101300031A - 用sdf-1治疗和/或预防神经疾病 - Google Patents

用sdf-1治疗和/或预防神经疾病 Download PDF

Info

Publication number
CN101300031A
CN101300031A CNA2006800404916A CN200680040491A CN101300031A CN 101300031 A CN101300031 A CN 101300031A CN A2006800404916 A CNA2006800404916 A CN A2006800404916A CN 200680040491 A CN200680040491 A CN 200680040491A CN 101300031 A CN101300031 A CN 101300031A
Authority
CN
China
Prior art keywords
sdf
application
disease
lys
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800404916A
Other languages
English (en)
Chinese (zh)
Inventor
U·博谢特
A·普罗德富特
L·卡迪
P·A·怀特
J·武伊齐克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Laboratories UK Ltd filed Critical Serono Laboratories UK Ltd
Publication of CN101300031A publication Critical patent/CN101300031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CNA2006800404916A 2005-10-31 2006-10-30 用sdf-1治疗和/或预防神经疾病 Pending CN101300031A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05110206 2005-10-31
EP05110206.9 2005-10-31
US60/734,142 2005-11-07

Publications (1)

Publication Number Publication Date
CN101300031A true CN101300031A (zh) 2008-11-05

Family

ID=35967039

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800404916A Pending CN101300031A (zh) 2005-10-31 2006-10-30 用sdf-1治疗和/或预防神经疾病

Country Status (14)

Country Link
US (1) US20080253996A1 (enExample)
EP (1) EP1942940A2 (enExample)
JP (1) JP2009513689A (enExample)
KR (1) KR20080060226A (enExample)
CN (1) CN101300031A (enExample)
AR (1) AR058173A1 (enExample)
AU (1) AU2006310577B2 (enExample)
BR (1) BRPI0617823A2 (enExample)
CA (1) CA2617598A1 (enExample)
EA (1) EA015716B1 (enExample)
NZ (1) NZ565639A (enExample)
UA (1) UA96926C2 (enExample)
WO (1) WO2007051785A2 (enExample)
ZA (1) ZA200800981B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325187A (zh) * 2017-07-19 2017-11-07 黄子为 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9249204B2 (en) * 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
WO2012170495A1 (en) * 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US11419916B2 (en) * 2012-09-11 2022-08-23 Energesis Pharmaceuticals, Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US9797910B2 (en) 2013-06-19 2017-10-24 Merck Sharp & Dohme Corp. Assay for determining endogenous levels of analyte in vivo
CN106796621B (zh) * 2014-09-10 2021-08-24 皇家飞利浦有限公司 图像报告注释识别
ITUA20161364A1 (it) 2016-03-04 2017-09-04 Antonino Cattaneo Inibitore di tnf alpha astrocitario per l’uso nel trattamento di malattie neurologiche.
WO2018144817A1 (en) * 2017-02-03 2018-08-09 Vicapsys, Inc. Modified cxcl12 polypeptides and uses thereof
US11553871B2 (en) 2019-06-04 2023-01-17 Lab NINE, Inc. System and apparatus for non-invasive measurement of transcranial electrical signals, and method of calibrating and/or using same for various applications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013095A1 (en) 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DE10027383A1 (de) * 2000-06-02 2001-12-20 Rhein Biotech Proz & Prod Gmbh Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107325187A (zh) * 2017-07-19 2017-11-07 黄子为 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物
CN107325187B (zh) * 2017-07-19 2021-11-09 黄子为 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物

Also Published As

Publication number Publication date
EP1942940A2 (en) 2008-07-16
BRPI0617823A2 (pt) 2011-08-09
AR058173A1 (es) 2008-01-23
AU2006310577A1 (en) 2007-05-10
US20080253996A1 (en) 2008-10-16
UA96926C2 (ru) 2011-12-26
JP2009513689A (ja) 2009-04-02
EA015716B1 (ru) 2011-10-31
AU2006310577B2 (en) 2012-04-19
CA2617598A1 (en) 2007-05-10
KR20080060226A (ko) 2008-07-01
NZ565639A (en) 2012-03-30
EA200801244A1 (ru) 2009-02-27
WO2007051785A3 (en) 2007-09-07
ZA200800981B (en) 2009-04-29
WO2007051785A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US8557769B2 (en) Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose
CA2832581C (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP2250193B1 (en) Postsynaptically targeted chemodenervation agents and their methods of use
KR20240025721A (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
SK14232003A3 (sk) Použitie osteopontínu alebo agonistu osteopontínovej aktivity
JP2010536801A (ja) Ｎａｐ様ペプチド擬似体およびｓａｌ様ペプチド擬似体を用いた神経保護法
HRP20040877A2 (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
CN110536692A (zh) 用于治疗糖尿病的含有atpif1的药物组合物
JP2020509011A (ja) エリスロポエチン由来ペプチドの細胞損傷防止に対する効果を介した活用
AU2006310577B2 (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
US20070134260A1 (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
EP1799248B1 (en) Use of il-17f for the treatment and/or prevention of neurologic diseases
HK1123210A (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
JP2007534746A (ja) 化学療法誘発性ニューロパシーの治療または予防のためのｉｌ−６
JP5048658B2 (ja) 神経性炎症性疾患の治療、及び／又は予防のためのｉｌ−１８ｂｐアイソフォームの使用
HK1087353A (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123210

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: MERCK SERONO CO., LTD.

Free format text: FORMER OWNER: SERONO LABORATORIES LTD.

Effective date: 20100324

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100324

Address after: Swiss Coyne Hince

Applicant after: Merck Serono S. A.

Address before: Swiss Coyne Hince

Applicant before: Serono Lab

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1123210

Country of ref document: HK